The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash collections from financial royalty assets | 915,598 | 916,130 | 882,358 | 726,525 |
| Cash collections from intangible royalty assets | 3,773 | 39 | 264 | 240 |
| Other royalty cash collections | 33,616 | 29,104 | 29,107 | 24,051 |
| Distributions from equity method investees | 3,722 | 0 | 0 | 0 |
| Interest received | 6,497 | 6,373 | 7,248 | 8,662 |
| Development-stage funding payments | 25,500 | 50,500 | 50,500 | 351,000 |
| Payments for operating and professional costs | 36,251 | 58,242 | 34,175 | 94,025 |
| Payments for employee epas | 9,696 | 9,075 | 1,695 | 173 |
| Interest paid | 173,526 | 6,681 | 129,992 | 796 |
| Net cash provided by operating activities | 718,233 | 827,148 | 702,615 | 363,984 |
| Acquisition of businesses, net of cash acquired | - | 0 | 226 | 74,190 |
| Distributions from equity method investees | 42,306 | 4,994 | 905 | 62,988 |
| Investments in equity method investees | - | 0 | 0 | 0 |
| Purchases of equity securities | 22,500 | 54,000 | 0 | 0 |
| Proceeds from equity securities | 375 | 34,723 | 0 | 0 |
| Purchases of available for sale debt securities | - | 100,000 | 0 | 75,000 |
| Proceeds from available for sale debt securities | 4,320 | 2,880 | 2,880 | 2,880 |
| Proceeds from sales of available for sale debt securities | 0 | 0 | 0 | 0 |
| Proceeds from sales and maturities of marketable securities | - | 0 | - | - |
| Acquisitions of financial royalty assets | 452,366 | 733,685 | 961,873 | 1,114 |
| Acquisitions of other financial assets | - | 0 | 0 | 0 |
| Milestone payments | 50,000 | 2,713 | 0 | 218,600 |
| Other | - | 0 | 0 | 8,946 |
| Net cash (used in)/provided by investing activities | -477,865 | -847,801 | -958,314 | -311,982 |
| Distributions to legacy non-controlling interests - portfolio receipts | 77,973 | 79,149 | 203,462 | 268,743 |
| Distributions to continuing non-controlling interests | 39,880 | 40,756 | 34,281 | 38,605 |
| Dividends to shareholders | 104,490 | 94,343 | 95,312 | 93,241 |
| Repurchases of class a ordinary shares | 50,100 | 80,537 | 146,493 | 291,572 |
| Contributions from legacy non-controlling interests - r&d | 0 | 0 | -219 | 219 |
| Contributions from non-controlling interests - other | 0 | 0 | 15 | 4,605 |
| Cash acquired in connection with purchase of non-controlling interest | - | 0 | - | - |
| Proceeds from revolving credit facility | - | 0 | 1,275,000 | - |
| Repayment of revolving credit facility | - | 0 | 1,275,000 | - |
| Repayment of long-term debt | - | 0 | 1,000,000 | - |
| Proceeds from issuance of long-term debt, net of discount | - | 0 | 1,954,475 | 0 |
| Debt issuance costs and other | - | 3,020 | 13,543 | 0 |
| Other | -226 | -1,790 | 0 | 0 |
| Net cash used in financing activities | -272,669 | -299,595 | 562,735 | -507,814 |
| Net change in cash and cash equivalents | -32,301 | -320,248 | 307,036 | -455,812 |
| Cash and cash equivalents, beginning of period | 618,696 | 938,944 | 631,908 | 1,087,720 |
| Cash and cash equivalents, end of period | 586,395 | 618,696 | 938,944 | 631,908 |
Royalty Pharma plc (RPRX)
Royalty Pharma plc (RPRX)